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Abstract
Background: The yeast Candida is one of the most frequent pathogens isolated from bloodstream infections and
is associated with significant morbidity and mortality. Problems with clinical and microbiological diagnosis of
invasive candidiasis (IC) have prompted the development of non-culture-based laboratory methods. Previous
reports suggest that serological detection of antibodies might be useful for diagnosing systemic candidiasis.
Methods: Diagnosis of IC using antibodies against recombinant Candida albicans enolase (Eno) and
fructose-bisphosphate aldolase (Fba1) was evaluated. Using recombinant Eno and Fba1 as coating antigens,
enzyme-linked immunosorbent assays (ELISAs) were used to analyze sera from patients with candidemia (n = 101),
Candida colonization (n = 50), bacteremia (n = 84), invasive aspergillosis (n = 40); and from healthy controls (n = 200).
Results: The results demonstrated that ELISA detection of anti-Eno and anti-Fba1 IgG distinguished IC from other
pathogenic infections in patients and healthy individuals. The sensitivity, specificity, and positive and negative
predictive values were 72.3%, 94.7%, 78.5% and 93% for anti-Eno, and 87.1%, 92.8%, 76.5% and 96.4% for anti-Fba1
antibodies, respectively. Combining these two tests improved sensitivity up to 90.1% and negative predictive value
up to 97.1%, with specificity and positive predictive values of 90.6% and 72.2%. The tests were specific to the
Candida genus and antibody titers were higher for candidemia patients than for controls. Positive antibody tests
were obtained before blood culture results for 42.2% of patients for anti-Eno and 51.1% for anti-Fba1.
Conclusion: These data suggest that tests that detect IgG antibodies against Candida enolase and
fructose-bisphosphate aldolase, especially when used in combination, could be a powerful tool for diagnosing IC.
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Background
Candida species are among the pathogens most fre-
quently isolated from bloodstream infections, and are as-
sociated with significant morbidity and mortality [1,2].
Infection by Candida species can involve any organ with
severity ranging from mucosal or cutaneous infections to
lethal invasive disease. In addition to hematological dis-
ease, prolonged hospitalization with treatment by broad
spectrum antibiotics, intravascular catheters, intensive
care unit hospitalization and gastrointestinal surgery put
patients at substantial risk of invasive infections [3,4].
Since the signs and symptoms of invasive candidiasis
(IC) are nonspecific, diagnosis remains a challenge. A
positive blood culture is considered the gold standard
for candidemia diagnosis. However, a relatively low sen-
sitivity (less than 50% according to previous studies), es-
pecially in the early period of infection, dramatically
hampers the value of blood culturing in clinical practice
[5]. We observed that in some cases, a patient with a
positive blood culture will test negative without anti-
fungal treatment after removal of intravenous catheters.
Thus, positive blood cultures can also be caused by fit-
ted intravascular catheters rather than invasive infection
(data not shown). The recovery of Candida from spu-
tum is usually considered to indicate colonization, but
should not be treated with antifungal therapy [6]. Other
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standard techniques for IC diagnosis including micro-
scopic visualization of the infecting fungus and histo-
pathology, usually lack specificity or sensitivity or
require invasive procedures that cannot be performed
because of the patient’s condition [5].
Recently investigations have focused on serological
tests for diagnosing IC. Detection of Candida anti-
gens and antibodies in serum samples are of practical
clinical value [7-18]. Antibody assays are commer-
cially available for (1→ 3)-β-D-glucan (BDG), a poly-
saccharide cell wall component of many fungi, and for
Candida mannan antigen and antimannan. A meta-
analysis [19] reported variable diagnostic performance
for BGD assays with sensitivity 50%–85% and specifi-
city 80%–99%. Individually, sensitivities were 58% for
mannan antigen and 59% for antimannan antibody as-
says. When used together, assay sensitivity increased
to 83% with no significant reduction in specificity
[20]. Therefore, IC diagnosis is now recommended to
be by serological tests for different antigens and anti-
bodies used in combination.
The specific antibody response to Candida proteins
that is usually induced in both immunocompromised
and immunocompetent patients by invasive Candida in-
fections is helpful in diagnosis [9,21]. However, antibody
detection methods have limitations. First, methods trad-
itionally used to detect antibodies are based on crude
antigenic fungal extracts that usually show crossreactivity
and low reproducibility. Second, immunocompromised
patients can produce low or undetectable levels of anti-
bodies, leading to false negative results. These problems
could be solved, at least in part, by using suitable anti-
gens and developing more sensitive antibody detection
techniques [17,18]. Advances in molecular biology, genom-
ics, proteomics, and bioinformatics are resulting in new
strategies for more sensitive and specific diagnostic tests
[22-24]. Using serological proteome analysis, 15 immuno-
genic proteins from lysates of C. albicans protoplasts were
identified and differentially immunorecognized by serum
IgG antibodies from IC patients compared to controls.
This result provides candidate antigens that can be pro-
duced in large amounts in a prokaryotic host, making
standardization easier and eliminating crossreactivity from
posttranslational modifications [23]. In another study,
enzyme-linked immunosorbent assays (ELISAs) measured
serum antibody responses against recombinant C. albicans
antigens in patients with IC and uninfected controls [18].
The results suggest that IgG response to a panel of Can-
dida antigens might be an accurate and early marker of IC.
Among the IgG antibodies, those against enolase (Eno)
and fructose-bisphosphate aldolase (Fba1) showed high
specificity and sensitivity in ELISA. Eno and Fba1 are well-
studied, phase-specific proteins that are expressed on the
cell wall of the germ tubes and hyphae of C. albicans [23].
Their location on the cell surface and loose association
with the cell wall might facilitate the production of anti-
bodies by C. albicans-infected hosts [24,25]. Eno and Fba1
are glycolytic and fermentation enzymes that catalyze op-
posing reactions during gluconeogenesis. They might be
required for IC virulence and could serve as vaccine pro-
teins [26-28]. Since the kinetics of antibody production
vary among patients [17], detection of a combination of
antibodies against different antigens in a single assay could
optimize diagnosis.
In this study, we report the serodiagnosis of infection
by invasive Candida species using ELISA to detect spe-
cific antibodies against recombinant Eno and Fba1. The
specificities of each marker in patients with candidemia,
Candida colonization, bacteremia, and invasive aspergil-
losis were confirmed; the sensitivities of detecting a sin-
gle marker and a combination of two markers were also
compared.
Methods
Patients and control subjects
All patients were admitted to Jingling hospital, Nanjing,
China, from January 2009 to December 2011. Four
non-overlapping patient groups were identified: (1) the
Candidemia group (n = 101), (2) the Candida colonization
group (n = 50), (3) the bacteremia group (n = 84), (4) the
invasive aspergillosis (IA) group (n = 40). Below are defini-
tions in this study. (1) Candidemia was defined as the isola-
tion of Candida species from the bloodstream in at least
one blood culture. (2) Candida colonization was defined as
the presence of a positive Candida species culture from
sputum only, none of these patients had a positive blood
culture for Candida species but positive for other organ-
isms. (3) the bacteremia was microbiologically defined by
positive culture of blood and (4) IA was defined according
to the EORTC-MSG criteria [29]. The sera (n = 200)
of healthy control subjects were from the volunteers
who did not have any clinical or microbiological evi-
dence of infection. The study protocol was approved
by the Ethics Committee of Jingling Hospital and in-
formed consent was obtained from all patients in-
cluded in the study. All data, including age, primary
condition, and clinical stage, outcome of hospital stay
were obtained from the clinical records.
Collection of sera
All of the serum samples drawn for clinical laboratory tests
from each candidemia patients were collected for our
study. The first serum was obtained one week before the
first positive culture presented. Subsequently, serum sam-
ples were obtained twice a week until the patient being
discharged or died. Serum samples from 50 patients with
Candida colonization and 84 patients with bacteremia
were collected on the date of positive culture. Sera of IA
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patients were from our previous research [30,31]. All sera
were stored at −80°C.
Identification of organisms
The blood was inoculated into a BacT-ALERT aerobic
vial (Becton Dickinson). All positive cultures were manu-
ally sampled and inoculated on CHROMagar Candida
medium (Hardy Laboratories, Santa Maria, Calif.) to en-
sure viability and purity. An aliquot was Gram-stained for
preliminary identification of the microorganism. Identifica-
tion of all species was confirmed with the Vitek-2 system
(bioMerieux, France).
Generation of recombinant Eno and Fba1
Primers were designed to clone and express full-
length protein. 5′-TACCATATGTCTTACGCCACTAAA
ATCC-3′ and 5′-ACTGGATCCTTACAATTGAGAAGC
CTTTGG-3′ for enolase, and (5′-GCACATATGGCTC
CTCCAGCAGTTTTAAG −3′) and (5′-GCAGGATCC
TTACAATTGTCCTTTGGTGTG −3′) for fructose-
bisphosphate aldolase. PCR products were cloned into the
pET-28a (+) expression vector (Novagen, Germany).
All inserts were confirmed by DNA sequencing. The
plasmids were transformed into Escherichia coli BL21
(DE3) cells (Novagen). Expression of recombinant antigens
was induced by isopropyl-β-D- thiogalactopyranoside
(IPTG). His6-tagged recombinant proteins were confirmed
by 15% SDS-PAGE, which showed a single band of
the expected size. Recombinant antigens were purified
from cell-free supernatants by chromatography on Ni2+ -
nitrilotriacetic acid-agarose in accordance to manufac-
turer’s instructions (Novagen). Fractions containing
purified recombinant proteins were pooled, dialyzed
against PBS and stored at −70°C.
ELISA
Preliminary checkerboard titration experiments were
performed to determine the optimal concentration of
antigen by comparing known positive and negative hu-
man sera. Microtiter plates (Costar, Cambridge, Mass,
USA) were coated with purified recombinant proteins
(1 μg/ml). Antigen was diluted in 0.05 M sodium car-
bonate buffer (pH 9.6) and 100 μl was added to each
well before incubating at 4°C overnight. After coating,
wells were washed once with PBS-T (PBS containing
0.5% Tween 20) and blocked with PBS-T containing
5% bovine serum albumin (BSA) for 1 h at 37°C. Sera
were diluted 1:500 in PBS-T and assayed in triplicate
(100 μl/well). After 1 h at 37°C, wells were washed
three times with PBS-T. Then, 100 μl of a 1:10,000 di-
lution of horseradish peroxidase (HRP)-conjugated goat
antihuman IgG (Signalwayantitibody, USA, L3012) in
PBS-T was added to each well and plates were incu-
bated at 37°C for 1 h. Plates were washed three times
with PBS-T followed by 100 μl of substrate solution
(3,3′,5,5′-tetramethylbenzidine, TMB) per well. Plates
were incubated at room temperature for 20 min in dark-
ness. Reactions were stopped by 50 μl per well of 0.5 M
sulphuric acid and absorbance was measured at 450 nm
using an automated ELISA plate reader (Microplate
reader, Bio-Rad Model 680). The mean absorbance for
each serum was calculated.
The block assay was used to confirm the specificity of
the ELISA. The sera that were intensively positive by
ELISA were diluted and incubated with 2.5 μg/ml re-
combinant antigens at 37°C for 1 h before ELISA. In
order to check the His-tag cross-reactivity, His6-Eno and
His6-Fba1 were replaced with His6-TR (a recombinant
protein of A. fumigatus with low homology to most
other fungi) [30] as coating antigen in ELISA.
Statistical analysis
For continuous variables, differences were analyzed by
the Mann–Whitney U test. For categorical variables, a
chi-square test was employed. A p values less than 0.05
was considered statistically significant. Sensitivity of
diagnostic techniques was calculated from proven cases.
Specificity was calculated from control groups. Statistical
analysis was performed using SPSS for Windows version
16.0 (SPSS Inc.).
Results
Study population and sera collection
The study population was classified by age, gender,
underlying disease, risk factors, and outcome of hospital
stay (Table 1). Candida isolates were classified to the
species level (Table 2). The number of sera per patient
was varying, from 2 to 25. So, 1015 serum samples
were obtained from 101 patients with candidemia.
The sera from 84 patients with bacteremia were
obtained, the bacteria infected including 47 Gram-
positive coccal species: 36 Staphylococcus, 4 Strepto-
coccus, 4 Enterococcus, 3 other Gram-positive cocci;
26 Gram-negative bacilli species: 11 Escherichia coli, 5
Klebsiella pneumonia, 3 Acinetobacter baumannii, 3
Serratia marcescens, 4 Pseudomonas aeruginosa; and
11 other gram negative bacilli.
Characterization of recombinant Eno and Fba1
Recombinant antigens were expressed as His6-tagged
proteins in E. coli cells and appeared as single bands of
expected sizes by SDS-PAGE, with molecular mass of
48 kDa for Eno and 39 kDa for Fba1 (Figure 1).
Analytical validation of ELISA assays
Serum samples from 101 patients with candidemia and
374 serum samples from control groups were tested. The
cut-off value for serum anti-Eno and anti-Fba1 was set by
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Table 1 Base-line characteristics of the 475 subjects and results of serum testing
Characteristic












n = 101 n = 50 n = 84 n = 40 n = 200
Demographic factors
Sex
Male 63 (73.0, 82.5)f 41 (7.3; 7.3) 52 (3.8,19.2) 33 (6.1; 0) 117 (2.6; 5.1)
Female 38 (71.1, 94.7) 9 (22.2; 22.2) 32 (6.3; 9.4) 7 (14.3; 14.3) 83 (1.2; 2.4)
Age (years, mean ± SD) 52.3 ± 19.6 76.12 ± 14.89 51.9 ± 14.2 57.6 ± 15.8 59.1 ± 12.4
≤65 years 71 (69.0, 87.3)g 9 (22.2; 44.4) 48 (6.3; 14.6) 28 (3.6; 0) 108 (1.9; 4.6)
>65 years 30 (80.0, 86.7) 41 (7.3; 2.4) 36 (2.8; 16.7) 12 (16.7; 8.3) 92 (2.2; 3.3)
Primary condition
Hematological malignancy 10 (60.0; 80.0) 3 (33.3; 33.3) 6 (33.3; 33.3) 1 (0; 0) 0
Leukemia 5 (40.0; 80.0) 1 (0; 0) 3 (33.3; 33.3)
Lymphoma 3 (100.0; 66.7) 1 (100.0; 100.0) 2 (50.0; 50.0)
Myelodysplasia 1 (0; 100.0) 1 (0; 0) 1 (0; 0)
Multiple myeloma 1 (100.0; 100.0) 0 (0; 0) 0 (0; 0) 1 (0; 0)
Solid tumor 11 (45.5; 81.8) 7 (14.3; 28.6) 10 (0; 30.0) 0 0
Bronchopulmonary neoplasm 2 (50.0; 50.0) 1 (0; 0) 4 (0; 50.0)
Pancreas/colon adenocarcinoma 7 (71.4; 85.7) 6 (16.7; 33.3) 5 (0; 20)
Bladder neoplasm 2 (50.0; 100.0) 0 (0; 0) 1 (0; 0)
Nonmalignant diseases 80 (77.5; 88.8) 40 (7.5; 5.0) 68 (2.9; 11.8) 39 (7.7; 2.6) 0
Respiratory dysfunctionb 5 (80.0; 60.0) 18 (11.1; 5.6) 3 (33.3; 33.3) 21 (4.8; 4.8)
Gastrointestinal pathologyc 65 (75.4; 92.3) 4 (25.0; 25.0) 60 (1.7; 11.7) 2 (100.0; 0)
Othersd 10 (90.0; 80.0) 18 (0; 0) 5 (0; 0) 16 (0; 0)
Risk factors
Iatrogenic predisposing factors
Broad spectrum antibiotics 68 (76.5; 86.8)h 44 (4.5; 2.3) 64 (4.7; 9.4) 20 (5.0; 5.0) 0
Glucocorticoids therapy 57 (87.7; 91.2) 40 (2.5; 2.5) 46 (2.2; 2.2) 0 (0; 0) 0
Central venous catheters 36 (72.2; 88.9) 28 (0; 0) 27 (0; 0) 9 (0; 0) 0
Parenteral nutrition 56 (82.1; 92.9) 15 (0; 0) 49 (0; 0) 3 (66.7; 0) 0
Other risk factors
Intensive care unit stay 26 (80.8; 92.3)i 12 (8.3; 16.7) 18 (5.6; 11.1) 12 (16.7; 0) 0
Neutropeniae 11 (36.4; 45.5) 2 (0; 50.0) 3 (0; 33.3) 0 (0; 0) 0
Acute renal failure 2 (50.0; 50.0) 2 (50.0; 0) 1 (100.0; 0) 0 (0; 0) 0
Outcome of hospital stay
Death 36 (63.9; 88.9)j 8 (37.5; 50.0) 10 (20.0; 50.0) 12 (8.3; 8.3)1,1 nk
Discharge 65 (76.9; 86.2) 42 (4.8; 2.4) 74 (2.7; 10.8) 28 (7.1; 0) nk
a Patients with proven and probable IA.
bIncludes the following diseases: pneumonia, chronic obstructive pulmonary disease, and acute respiratory distress syndrome.
c Includes the following diseases: cholecystitis, angiocholitis, pancreatitis, peritonitis, and hepatitis.
d Includes the following diseases: multiple trauma, acute renal insufficiency, and diabetes mellitus.
e Neutropenia was defined as an absolute neutrophil count below 500 cells/mm3.
f,g,h,I,j No significant difference was found in patients with candidemia associated with age, sex, predisposing factors for IC and clinical outcomes (P > 0.05).
k Not applicable.
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receiver operating characteristic curves with A = 0.370
for anti-Eno and A = 0.610 for anti-Fba1. Patient sera
were regarded as positive when ELISA results were
above these cut-off points at a serum dilution of 1:500.
Sera with positive test results were diluted two-fold until
the test results became negative. Titers were defined as
the highest serum dilution with a positive result. The
specificity of the ELISA was confirmed by the block
assay. The absorbance was reduced by 93.0% for anti-Eno
and 85.3% for anti-Fba1 after intensively positive sera incu-
bated with antigens. When His6-Eno and His6-Fba1 were
replaced with His6-TR, no substantial His6-tag cross-
reactivity was detected.
Detection of antibodies in patients
A total of 1015 serum samples from 101 patients with
candidemia were tested. The median anti-Eno antibody ab-
sorbance was significantly higher for sera from candidemia
patient (0.682; interquartile range, 0.522–0.849) than
for sera from non-IC patients (0.282; interquartile range,
0.175–0.368; P < 0.001) or healthy individuals (0.188;
interquartile range, 0.156–0.227; P < 0.001). Likewise,
candidemia patients had a greater prevalence of seroposi-
tive anti-Fba1 antibody (1.156; interquartile range, 0.930-
1.322) than non-IC patients (0.317; interquartile range,
0.189-0.488; P < 0.001) or healthy individuals (0.316; inter-
quartile range, 0.235-0.410; P < 0.001), as shown in Figure 2.
Table 2 IgG antibodies and microbiological surveillance of patients with candidemia and Candida colonization
Microorganism
Anti-Eno Anti-Fba1
Candidemia Candida colonization Candidemia Candida colonization
n No. (%) positive n No. (%) positive n No. (%) positive n No. (%) positive
C. albicans 25 21 (84.0) 37 1 (2.7) 25 23 (92.0) 37 2 (5.4)
C. tropicalis 20 9 (45.0) 7 1 (14.3) 20 16 (80.0) 7 2 (28.6)
C. parapsilosis 21 18 (85.7) 1 0 (0) 21 19 (90.5) 1 0 (0)
C. glabrata 10 7 (70.0) 3 2 (66.7) 10 8 (80.0) 3 1 (33.3)
C.guilliermondii 5 3 (60.0) — — 5 5 (100.0) — —
Candida spp. 20 15 (75.0) 2 1 (50.0) 20 17 (85.0) 2 0 (0)
Total 101 73 (72.3)a 50 5 (10.0) 101 88 (87.1)b 50 5 (10.0)
X
2
a =51.94, P < 0.01; X
2
b =84.1, P < 0.01, when compared with the control (patients with candida colonization).
Figure 1 SDS-PAGE of recombinant enolase (Eno) and fructose-bisphosphate aldolase (Fba1). A. Lanes: 1, pET28a-Eno in E. coli BL21;
2, pET28a-Eno in E. coli BL21, induced by IPTG; 3, purified recombinant Eno. B. Lanes: 1, pET28a-Fba1 in E. coli BL21; 2, pET28a-Fba1 in E. coli BL21,
induced by IPTG; 3, purified recombinant Fba1. Molecular markers (in kDa) of standard proteins are to the left.
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Figure 2 Antibody levels in study patients (A: anti-Eno and B: anti-Fba1). Patients with candidemia, Candida colonization, bacteremia, invasive
aspergillosis and healthy controls were evaluated for the presence of anti-Eno and anti-Fba1 antibodies. The levels of anti-Eno and anti-Fba1 in patients
with candidemia were higher than control groups. Boxes indicate interquartile ranges (25–75th percentiles). Horizontal bars in bold indicate the median
value in each group. Whiskers extend to 1.5 times the interquartile range. *P< 0.001, for the comparison with the patients with candidemia; **P< 0.001,
for the comparison with the patients with candidemia.
Figure 3 Anti-Eno and anti-Fba1 antibody titers in patients with candidemia and control groups. A, anti-Eno titers; B, anti-Fba1 titers. In
73 anti-Eno positive patients, 32 at a titer of 1:500, 41 at titers ≥1:1000. In 88 anti-Fba1 positive patients, 81 were tested titers, 33 at a titer of
1:500, 48 at titer ≥1:1000. In 15 anti-Eno positive control individuals, only one at a titer of 1:1000. In 26 anti-Fba1 positive control individuals, 3 at a
titer of 1:1000. None control individuals at titer >1:1000.
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Serological and microbiological surveillance of patients
with candidemia and Candida colonization are in Table 2.
The anti-Eno and anti-Fba1 antibody titers in candidemia
patients were significantly higher than in control groups
(Figure 2 and Figure 3). Although anti-Eno and anti-Fba1
antibodies were detected in some individuals in the control
groups at a titer of 1:500, greatly reduced in number at ti-
ters 1: 1000 (only one patients with Candida colonization
and two pateint with bacteremia), these samples were all
negative at titers >1: 1000. No significant differences in
these levels were found among control groups. Patients
infected with C. albicans and control groups were more
likely to have antibody against Fba1, in C. albicans-infected
patients, 84% (21/25) were positive for anti-Eno and
92% (23/25) were positive for anti-Fba1, while in
non-C. albicans infected patients, 68.4% (52/76) were
positive for anti-Eno and 85.5% (65/76) were positive
for anti-Fba1, but no significant differences were found
between groups (84% vs 68.4%, X2 = 2.28, p > 0.05; 92%
vs 85.5%, X2 = 0.703, p > 0.05). For candidemia, neither
the seroprevalence nor the titers of the identified anti-
bodies were significantly associated with age, sex, and
predisposing factors for IC, causative Candida species,
or clinical outcomes (Table 1). The combined detection
of anti-Eno and anti-Fba1 (sera gave single or both
assay positive result were regarded as positive, Table 3)
gave a sensitivity of 90.1%, specificity of 90.6%, positive
predictive value of 72.2%, and negative predictive value
of 97.1%. The availability of serial consecutive serum
samples from candidemia patients allowed us to study
the kinetics of the antibody response to Eno and Fba1
by ELISA. Anti-Eno and anti-Fba1 antibodies were
detected in 50% of non-neutropenia patients before the
diagnosis of candidemia made blood culture. However,
the seroprevalence of antibodies was reduced in neu-
tropenia patients (Table 4).
Discussion
We report the development of two ELISAs for serodiag-
nosis of invasive Candida infections. The assays detect
specific IgG antibodies against recombinant Eno and
Fba1. We evaluated the diagnostic value of the assays by
comparing patients and diverse control participants. We
measured antibodies against Eno and Fba1 in patients
with candidemia, Candida colonization, bacteremia, and
invasive aspergillosis; and in healthy controls. The re-
sults revealed that both Eno and Fba1 were specific
for the Candida genus, and that recombinant antigens
from C. albicans reacted with sera from candidemia
patients infected with C. albicans and other Candida
species including C. tropicalis, C. parapsilosis, C. glabrata,
C. guilliermondii. Both the seroprevalence and serum levels
of anti-Eno and anti-Fba1 in candidemia patients were
significantly higher than in control groups (Table 1 and
Figure 3). ELISA specificity was confirmed by block assay.
Several studies on the diagnostic utility of detecting
antibodies against Eno have had promising results
[9,10,18,32]. Láın et al. [9] described the performance of
a diagnostic ELISA to detect antibodies against recom-
binant enolase in 98 patients (47 immunocompromised
and 51 immunocompetent). The results were similar in
both patient groups, with sensitivities of 78.9% in immuno-
compromised and 82.6% in immunocompetent patients,
and specificities of 89.3% and 78.6%. These results confirm
Table 3 Diagnostic value of anti-Eno and anti-Fba1 on the
test cohort
Anti-Eno Anti-Fba1 Combination of anti-Eno
and anti-Fba1
True negative 354 347 339
False positive 20 27 35
True positive 73 88 91
False negative 28 13 10
Sensitivity (%) 72.3 87.1 90.1







The number of patients is presented in the upper part of the table. Sensitivity,
specificity, and positive and negative predictive values are estimated in
percentage calculated from patient responses. In the combined detection of
anti-Eno and anti-Fba1, sera with single or both assay positive results were
regarded as positive.
Table 4 Positive rate and timing of anti-Eno and anti-Fba1 antibodies in non-neutropenic and neutropenic patients




Ab* (+) prior to BC(+) BC**(+) prior to Ab(+) Total Ab(+) prior to BC(+) BC(+) prior to Ab(+) Total
Non-neutropenia (90) 38 (42.2) 31 (34.4) 69 (76.7) 46 (51.1) 37 (41.1) 83 (92.2)
Neutropenia# (11) 3 (27.3) 1 (9.1) 4 (36.4)a 4 (36.4) 1 (9.1) 5 (45.5)b
Total (101) 41 (40.6) 32 (31.7) 73 (72.3) 50 (49.5) 38 (37.6) 88 (87.1)
*Ab: antibody, ** BC: blood culture.
#Neutropenia was defined as an absolute neutrophil count below 500 cells/mm3.
aP = 0.005, for the comparison with the Non-neutropenia group.
bP < 0.001, for the comparison with the Non-neutropenia group.
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the utility of detecting recombinant enolase antibodies for
diagnosis of invasive candidiasis, even in immunocom-
promised patients. Our study detected anti-Eno and anti-
Fba1 antibodies in 90 non-neutropenic and 11 neutropenic
patients with candidemia. Of these, 76.7% (69/90) of the
non-neutropenic and 36.4% (4/11) of the neutropenic pa-
tients were seropositive. Our results suggested that the
diagnostic value of anti-Eno and anti-Fba1 antibodies was
limited in neutropenic patients (Table 4). Clancy et al. [18]
reported antibody responses against 15 recombinant anti-
gens from 12 proteins in 60 patients with systemic candid-
iasis and 24 uninfected controls. IgM and IgG titers against
the recombinant antigens were consistently detected by
ELISA. For all 15 antigens, IgG responses were superior to
IgM responses for discriminating patients with systemic
candidiasis from controls. IgG titers were detectable for
anti-Eno in 98.3% (59/60) of participants with system can-
didiasis and for anti-Fba1 in 93.3% (56/60); IgM titers were
detectable for anti-Eno in only 46.7% (28/60) of these pa-
tients and for anti-Fba1 in only 36.7% (22/60). Using dis-
criminating analysis that included IgG responses against
the 15 antigens, a mathematical prediction model was de-
veloped to identify patients with systemic candidiasis. The
model had an an error rate of 3.7%, a sensitivity of 96.6%,
and a specificity of 95.6%. Our study included more pa-
tients and controls than previous studies. For anti-Eno,
sensitivity was 72.3%, specificity was 94.7%, positive pre-
dictive value was 78.5% and negative predictive values was
93%; for anti-Fba1, these values were 87.1%, 92.8%, 96.4%
and 76.5%, respectively (Table 3). While the performance
of each assay alone was unremarkable, when the two tests
were combined, the sensitivity improved to 90.1% and and
negative predictive value improved to 97.1%. When devel-
oping disease screening strategies, maximizing the negative
predictive value is important for reliably identifying pa-
tients who are not likely to develop the disease. Therefore,
the combination of the anti-Eno and anti-Fba1 assays was
a favorable screening tool for IC.
In this study, collection of serial serum samples was
initiated one week before positive blood culturing, and
ended at discharge or death of the patient. In about 50%
patients, we obtained a positive detection of antibody
earlier than the positive blood culture. The explanation
for this result is that in our hospital, anti-fungal agents
are prescribed to patients with clinical suspicion of IC
before a positive blood culture is received. Anti-fungal
therapy might produce a false-negative blood culture re-
sult but should have no effect on an antibody test. Anti-
Fba1 usually appeared slightly earlier than anti-Eno, but
the mechanism of this difference is unknown. We also
found that serum IgG responses against selected two
Candida antigens discriminated candidemia from exclu-
sively Candida positive sputum cultures. These results
suggested that, patients with non-Candida infections,
only patients with positive sputum cultures might have
similar levels of anti-Eno and anti-Fba1.
Conclusion
In conclusion, our findings suggested that anti-Eno and
anti-Fba1 could be useful screening tools and early markers
of IC.
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